Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBITDA Margin: 2009-2024

Historic EBITDA Margin for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to 26.50%.

  • Ironwood Pharmaceuticals' EBITDA Margin rose 3385.00% to 61.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.34%, marking a year-over-year increase of 1012.00%. This contributed to the annual value of 26.50% for FY2024, which is 24004.00% up from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' EBITDA Margin is 26.50%, which was up 112.41% from -213.54% recorded in FY2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBITDA Margin peaked at 127.72% during FY2021, and registered a low of -213.54% during FY2023.
  • In the last 3 years, Ironwood Pharmaceuticals' EBITDA Margin had a median value of 26.50% in 2024 and averaged -48.14%.
  • In the last 5 years, Ironwood Pharmaceuticals' EBITDA Margin crashed by 25,618bps in 2023 and then soared by 24,004bps in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' EBITDA Margin (Yearly) stood at 27.26% in 2020, then skyrocketed by 10,046bps to 127.72% in 2021, then plummeted by 8,508bps to 42.64% in 2022, then slumped by 25,618bps to -213.54% in 2023, then surged by 24,004bps to 26.50% in 2024.